Kabir Nath

Kabir Nath, Chief Executive Officer of Compass Pathways, brings a dedication to mental health care to pursue one of the most ambitious undertakings in modern psychiatry – to potentially bring the first classical psychedelic to market as a new treatment for serious mental illness. Kabir knows how fragile mental health is, and how serious mental illness can drastically impact a person’s life with little warning, including ourselves and those closest to us. That lived proximity has elevated his commitment to innovation in mental health care from a professional pursuit into something closer to a life’s purpose.   

 

Kabir’s distinguished business leadership career spans nearly thirty years of global biopharmaceutical and medical device experience. Prior to joining Compass, he served as President and CEO of Otsuka Pharmaceutical’s North America Pharmaceutical Business and Senior Managing Director of Global Pharmaceuticals. He has held senior strategic and operational roles at Bristol-Myers Squibb, as well as Smith & Nephew, and has lived and worked in multiple countries across Asia and Europe as well as the USA.  Kabir began his career in strategy consulting at Booz Allen & Hamilton. He holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.